Navigation Links
Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications
Date:12/21/2009

claims to the extent not covered by insurance, our exposure to fluctuations in currency, exchange and interest rates, significant operations worldwide that may be adversely affected by terrorism, political or economical instability or major hostilities, our ability to enter into patent litigation settlements and the intensified scrutiny by the U.S. government, the termination or expiration of governmental programs and tax benefits, impairment of intangible assets and goodwill, environmental risks, and other factors that are discussed in this report and in our other filings with the U.S. Securities and Exchange Commission ("SEC").

OncoGenex's Forward Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning potential milestones, royalties and other payments that may be received by OncoGenex in the future, anticipated clinical and other product development activities and timing and costs of these activities, market potential for OGX-011 and success of activities to attain market approval and sales. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Such forward-looking statements are subject to risks and uncertainties, including, among others, the risk factors set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for fiscal year 2008. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring aft
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ATS Medical Expands Open Pivot Heart Valve Offerings
2. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
3. BioLife Solutions Expands Scientific Advisory Board
4. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
5. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
6. Pharsight Expands Strategic Consulting Services Team
7. Validus Pharmaceuticals Expands Product Portfolio with Acquisition of Bipolar Drug: Equetro(R)
8. Serica Technologies Expands Facilities in Massachusetts, Combines State-Of-The-Art Textile Engineering and Biomedical Manufacturing
9. AQUISS Expands Into Significant New Territory
10. NanoBio Expands Drug Development Team for Its Anti-Infective Products
11. BitWine (TM) Nutrition Advisors Network Expands Roster of Licensed Dietitians and Nutritionists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Pittsburgh, PA (PRWEB) January 15, 2014 The ... Company, publisher of Food Safety Tech , an e-Journal ... has signed an agreement for the second year for the ... with Pittcon 2014. The partnership provides that the registration fee ...
(Date:1/15/2014)... RedBrick Health , a fast-growing leader in consumer ... EmblemHealth , the New York ... the RedBrick Compass health assessment, combined with the RedBrick ... members. EmblemHealth is among the first health plans in ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains ... these latent viruses is the Epstein Barr Virus (EBV), and ... (RA) is a chronic inflammatory disease that destroys the body’s ... RA patients have high concentrations of EBV DNA in their ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that they ... Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ... , Turkey and other members ... antibiotic for the treatment of bacterial infections including those ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... BEIJING, Feb. 19 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex:,SVA), ... it,will hold its 2007 Annual Meeting of Shareholders on ... meeting will be held concurrently at,No. 39 Shangdi Xi ... Temple,Street, St. John,s, Antigua. All shareholders of record as ...
... Colo., Feb. 19 Pharmion Corporation,(Nasdaq: PHRM ) ... December 31, 2007. For the year, net sales totaled ... 2006. Worldwide sales of,Vidaza(R) (azacitidine for injection) totaled $165.3 ... the U.S., sales of Vidaza totaled,$131.4 million in 2007, ...
... Annual Revenues of $210.9 Million - Annual EPS ... - Annual EBITDASO of $4.03 per Basic Share, ... 19 United,Therapeutics Corporation (Nasdaq: UTHR ) today announced ... 2007., "We are pleased to report that United Therapeutics, ...
Cached Biology Technology:Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders 2Pharmion Corporation Announces 2007 Operating Results 2Pharmion Corporation Announces 2007 Operating Results 3Pharmion Corporation Announces 2007 Operating Results 4Pharmion Corporation Announces 2007 Operating Results 5Pharmion Corporation Announces 2007 Operating Results 6United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results 2United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results 3United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results 4United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results 5United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results 6United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results 7United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results 8United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results 9
(Date:4/17/2014)... Respiratory syncytial virus (RSV) is a leading cause ... in very young and elderly populations. Despite great ... cells through the fusion protein RSV F, which ... that prevent bundle formation limit RSV infection in ... degradation. In this issue of the Journal ...
(Date:4/17/2014)... Luca Razzari of the nergie Matriaux Tlcommunications Research ... the John R. Evans Leaders Fund of the ... of state-of-the-art biotech and nanophotonics equipment. To this ... Ministre de l,Enseignement suprieur, de la Recherche, de ... new laboratories will help us develop new approaches ...
(Date:4/17/2014)... marrow need to produce hydrogen sulfide in order to ... new study from the Center for Craniofacial Molecular Biology ... , Professor Songtao Shi, principal investigator on the project, ... cells governs the flow of calcium ions. The essential ... in osteogenesis, or the creation of new bone tissue, ...
Breaking Biology News(10 mins):JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6New state-of-the-art biotech and nanotech equipment for INRS 2
... decision-making tools for public health officials. As demonstrated ... models can be useful in two ways: they ... and they can allow the comparison of alternative ... assumptions that may systematically bias their predictions, say ...
... Mathematical models have become invaluable decision-making tools for ... Kingdom's foot-and-mouth epidemic of 2001, models can be ... underlying characteristics of an infection and they can ... however, such models make implicit assumptions that may ...
... discovered how to clone human embryos from eggs that ... make it easier for scientists to create embryonic stem ... provide eggs and sperm for infertile couples, the 21st ... and Embryology heard today (Monday 20 June). , Until ...
Cached Biology News:Field of beams - Novel system uses polarized light pulses to reveal crop health 2Inhaling large amounts of salt can cause hypertension 2Invitrogen Launches i-Path -- A Unique Systems Biology Platform at BIO 2005 2Invitrogen Launches i-Path -- A Unique Systems Biology Platform at BIO 2005 3
...
BD Falcon microtest assay plate. 1536 well 12l, black BD Optilux PS. Polystyrene, nonsterile, no lid (15/sp, 60/ca) Packaging: 15 / pack, 60 / case ...
... Black wall plates have low ... reduced crosstalk,• Not treated (or medium ... nature and binds biomolecules through passive ... the immobilization of large molecules, such ...
... ProFound Label Transfer Sulfo SBED Protein:Protein Interaction ... as Label Transfer has rapidly gained traction ... interaction discovery. A growing number of publications ... Label Transfer Reagent to study a variety ...
Biology Products: